Celcuity Trial Finds 21.5-Month Progression-Free Survival in Breast Cancer Subgroup

Celcuity Trial Finds 21.5-Month Progression-Free Survival in Breast Cancer Subgroup

Patients with PIK3CA-mutated disease and no liver metastases had median progression-free survival of 21.5 months on the gedatolisib triplet, versus 9.1 months on the control regimen.

Celcuity Inc. (CELC) Stock: Promising Phase 3 Breast Cancer Data Fuels Growth Hopes

TLDR CELC stock fell 0.49% to $65.25, then dipped another 1.39% after hours to $64.34. Gedatolisib triplet delivers 21.5 months without progression in one key subgroup. Triplet response rate reaches 59%, versus 33% for the control treatment group. Gedatolisib dropout rates hit 5% and 4%, versus 19% for alpelisib treatment. Eight-study analysis favors gedatolisib regimens [...]

Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026 - PressReach

Median PFS was 21.5 months with the gedatolisib triplet and 11.5 months with the gedatolisib doublet versus 9.1 months with alpelisib + fulvestrant in patients who had no liver metastases  ORR and median duration of response was 59% and 19.4 months for the gedatolisib triplet and 43% and 27.8 months for the gedatolisib doublet, respectively, compared to 33% and 7.5 months for alpelisib + fulvestrant The discontinuation rate for gedatolisib due t…

Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026